compounding is the most under-discussed thing on this board
compounding is the most under-discussed thing on this board, which sounds obvious until you try to state the evidence for it.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
if a clinic will not name the facility, that is your answer
the shortage list is the whole legal hinge and people skip it
Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.
Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
[removed by moderator]
What concentration is on the label, and does it match what you were expecting?
compounded is not generic, there is no equivalence claim
Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.
do not assume the concentration matches the branded product
ask which facility, then ask for their testing
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
the price difference is mostly the intake, not the vial
What did the intake actually ask you?
Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.
a 503B has to register and report, so there is a paper trail to ask for
This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.
- 1Yes. The shortage list is the legal hinge for the whole arrangement and its…7 comments in this branch · started by u/milos_mensa
- 2Not convinced. You are comparing a compounded concentration with a branded…6 comments in this branch · started by u/gustav_cardoso